Gabelli Funds LLC Cytokinetics Inc Transaction History
Gabelli Funds LLC
- $12.8 Billion
- Q3 2024
A detailed history of Gabelli Funds LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Gabelli Funds LLC holds 5,400 shares of CYTK stock, worth $252,828. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,400
Previous 5,000
8.0%
Holding current value
$252,828
Previous $270,000
5.56%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
405Shares Held
124MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$687 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$551 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$454 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$364 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$302 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.41B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...